WO2016127123A3 - Compounds and methods for preventing or treating sensory hair cell death - Google Patents

Compounds and methods for preventing or treating sensory hair cell death Download PDF

Info

Publication number
WO2016127123A3
WO2016127123A3 PCT/US2016/016880 US2016016880W WO2016127123A3 WO 2016127123 A3 WO2016127123 A3 WO 2016127123A3 US 2016016880 W US2016016880 W US 2016016880W WO 2016127123 A3 WO2016127123 A3 WO 2016127123A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
preventing
methods
cell death
hair cell
Prior art date
Application number
PCT/US2016/016880
Other languages
French (fr)
Other versions
WO2016127123A2 (en
Inventor
Julian Simon
Graham Johnson
Edwin W. Rubel
David W. Raible
Mario D. GONZALEZ
Peter C. Meltzer
Weishi Miao
Original Assignee
University Of Washington
Fred Hutchinson Cancer Research Center
Oricula Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2016215023A priority Critical patent/AU2016215023B2/en
Priority to US15/547,438 priority patent/US10399994B2/en
Priority to EP16747385.9A priority patent/EP3253766B1/en
Priority to JP2017538575A priority patent/JP6697808B2/en
Priority to CA2974395A priority patent/CA2974395C/en
Priority to CN201680020455.7A priority patent/CN107438613B/en
Application filed by University Of Washington, Fred Hutchinson Cancer Research Center, Oricula Therapeutics Llc filed Critical University Of Washington
Priority to ES16747385T priority patent/ES2760373T3/en
Priority to KR1020177025003A priority patent/KR102557184B1/en
Priority to DK16747385T priority patent/DK3253766T3/en
Publication of WO2016127123A2 publication Critical patent/WO2016127123A2/en
Publication of WO2016127123A3 publication Critical patent/WO2016127123A3/en
Priority to HK18106459.1A priority patent/HK1246791A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
PCT/US2016/016880 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death WO2016127123A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US15/547,438 US10399994B2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
EP16747385.9A EP3253766B1 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
JP2017538575A JP6697808B2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
CA2974395A CA2974395C (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
CN201680020455.7A CN107438613B (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
AU2016215023A AU2016215023B2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
ES16747385T ES2760373T3 (en) 2015-02-06 2016-02-05 Compounds and procedures to prevent or treat sensory hair cell death
KR1020177025003A KR102557184B1 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death
DK16747385T DK3253766T3 (en) 2015-02-06 2016-02-05 RELATIONSHIPS AND PROCEDURES FOR PREVENTION OR TREATMENT OF SANCIAL HAIR CELL DEATH
HK18106459.1A HK1246791A1 (en) 2015-02-06 2018-05-17 Compounds and methods for preventing or treating sensory hair cell death

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113245P 2015-02-06 2015-02-06
US62/113,245 2015-02-06

Publications (2)

Publication Number Publication Date
WO2016127123A2 WO2016127123A2 (en) 2016-08-11
WO2016127123A3 true WO2016127123A3 (en) 2016-10-27

Family

ID=56564889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/016880 WO2016127123A2 (en) 2015-02-06 2016-02-05 Compounds and methods for preventing or treating sensory hair cell death

Country Status (11)

Country Link
US (2) US9493482B2 (en)
EP (1) EP3253766B1 (en)
JP (1) JP6697808B2 (en)
KR (1) KR102557184B1 (en)
CN (1) CN107438613B (en)
AU (1) AU2016215023B2 (en)
CA (1) CA2974395C (en)
DK (1) DK3253766T3 (en)
ES (1) ES2760373T3 (en)
HK (1) HK1246791A1 (en)
WO (1) WO2016127123A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493482B2 (en) 2015-02-06 2016-11-15 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
JP7397487B2 (en) * 2017-09-01 2023-12-13 ユニヴァーシティ オブ ワシントン Crystalline Forms of Compounds for Preventing or Treating Sensory Hair Cell Death
WO2020033322A1 (en) * 2018-08-06 2020-02-13 Fred Hutchinson Cancer Research Center Hearing loss-protective compounds and methods thereof
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188445A1 (en) * 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
WO2012082331A1 (en) * 2010-12-15 2012-06-21 Trustees Of Dartmouth College Methods for screening antibiotic compounds
WO2014052914A1 (en) * 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES457780A1 (en) 1977-04-14 1978-08-16 Made Labor Sa 7,10-dimethyl-5,9-imino-4,5,8,9-tetrahydro-cycloocta(b)-thiophenes
ES462993A1 (en) 1977-10-07 1978-06-01 Made Labor Sa A procedure for the simultaneous obtaining of 6,7,10-trimethyl-5,9-imino-4,5,8,9-tetrahidrocicococta (b) furane and of alpha-2,4,5-trimethylphide (2,3- f) morphano. (Machine-translation by Google Translate, not legally binding)
US4174396A (en) 1978-04-03 1979-11-13 Laboratories Made, S.A. 7,10-Dimethyl-5,9-imino-4,5,8,9-tetrahydro-cyclooct[b]thiophenes and a process for obtaining it
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3684446D1 (en) 1985-12-28 1992-04-23 Sumitomo Pharma MEDICINAL PRODUCTS WITH DELAYED RELEASED RELEASE.
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
ES2111065T5 (en) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited PROCEDURE TO PRODUCE A SOLID DISPERSION.
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
WO1993009785A1 (en) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
ATE304545T1 (en) 2001-06-29 2005-09-15 Novo Nordisk As METHOD FOR INHIBITING TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE IN POSITION 48
US20070275962A1 (en) 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9493482B2 (en) 2015-02-06 2016-11-15 University Of Washington Compounds and methods for preventing or treating sensory hair cell death

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188445A1 (en) * 2005-02-22 2006-08-24 Fred Hutchinson Cancer Research Center Assay for compounds that protect against sensory hair cell death and compounds identified by same
WO2012082331A1 (en) * 2010-12-15 2012-06-21 Trustees Of Dartmouth College Methods for screening antibiotic compounds
WO2014052914A1 (en) * 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARHIN, F. ET AL.: "A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 14, no. 17, 2006, pages 5812 - 5832, XP027992856 *
OWENS, K. N. ET AL.: "Identification of genetic and chemical modulators of zebrafish mechanosensory hair cell death", PLOS GENETICS, vol. 4, no. 2, 2008, pages 1 - 14, XP055323638 *

Also Published As

Publication number Publication date
WO2016127123A2 (en) 2016-08-11
DK3253766T3 (en) 2019-12-09
US10399994B2 (en) 2019-09-03
AU2016215023B2 (en) 2019-12-19
US9493482B2 (en) 2016-11-15
ES2760373T3 (en) 2020-05-13
JP6697808B2 (en) 2020-05-27
CN107438613B (en) 2020-08-25
US20180022756A1 (en) 2018-01-25
AU2016215023A1 (en) 2017-09-07
KR20180003530A (en) 2018-01-09
HK1246791A1 (en) 2018-09-14
EP3253766A4 (en) 2018-07-25
CA2974395C (en) 2023-08-22
CN107438613A (en) 2017-12-05
EP3253766B1 (en) 2019-09-04
EP3253766A2 (en) 2017-12-13
US20160229869A1 (en) 2016-08-11
CA2974395A1 (en) 2016-08-11
JP2018504411A (en) 2018-02-15
KR102557184B1 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
WO2019099868A3 (en) Degraders and degrons for targeted protein degradation
MX2018002723A (en) Peptidomimetic macrocycles and uses thereof.
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2016127123A3 (en) Compounds and methods for preventing or treating sensory hair cell death
EP3638349A4 (en) Active agent delivery devices and methods for using the same
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
CR20170259A (en) POISON THERAPIES AND PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND RELATED EQUIPMENT
EP3534927A4 (en) Single dose methods for preventing and treating fungal infections
WO2016100738A3 (en) Antifibrotic activity of gas6 inhibitor
EP3651801A4 (en) Compositions and methods for the treatment of fungal infections
EP3801478A4 (en) Methods and compositions for preventing or treating calciphylaxis
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
WO2016130581A8 (en) Combination cancer therapy
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
BR112018072664A2 (en) compositions and methods for treating eye inflammation and infection
EP3838898C0 (en) Isoindolin-1-one derivative, method for preparing the same, and pharmaceutical composition comprising the same as an effective component for preventing or treating cancer
WO2017021855A3 (en) Motile sperm domain containing protein 2 and inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16747385

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017538575

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2974395

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15547438

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2016747385

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177025003

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016215023

Country of ref document: AU

Date of ref document: 20160205

Kind code of ref document: A